FY2026 Earnings Estimate for Amgen Issued By Leerink Partners

Amgen Inc. (NASDAQ:AMGN - Free Report) has recently seen a revision in earnings estimates from investment analysts at Leerink Partners. On February 5th, a report indicated an increase in their forecast for Amgen's fiscal year 2026 earnings per share (EPS). The analyst, D. Risinger, now anticipates that the biotechnology company will achieve earnings of $20.32 per share for FY2026, up from a previous estimate of $19.93.

Current Earnings Context

This new estimate stands above the current consensus expectation for Amgen's full-year earnings, which is pegged at $19.56 per share. In addition to the FY2026 estimate, Leerink Partners also provided projections for future years, estimating $20.70 EPS for FY2028 and $22.08 EPS for FY2029.

Recent Quarterly Earnings Report

On February 4th, Amgen released its quarterly earnings data, reporting earnings of $5.31 per share. This result surpassed the consensus estimate, which stood at $5.04, indicating a positive financial performance for the quarter. The company achieved a net margin of 13.00% and a significant return on equity of 168.35%, showcasing its profitability.

Analyst Ratings and Price Targets

Other analysts have also issued their evaluations of Amgen's stock. Bank of America raised its price target on Amgen shares from $256.00 to $275.00, giving the company an "underperform" rating. In contrast, Royal Bank of Canada maintained an "outperform" rating and set a price target of $324.00. Meanwhile, Wells Fargo reduced its target from $335.00 to $280.00, advising an "equal weight" rating. Currently, the stock analysts have given the stock a mix of ratings, with an average of "Hold" and a consensus price target of $314.83.

Amgen's Stock Performance

As of recent trading, Amgen stock opened at $297.78. The company's performance metrics reveal it has a market capitalization of $160.07 billion, a relatively high price-to-earnings ratio of 38.13, and a price-to-earnings-growth ratio of 2.87. Moreover, the company's debt-to-equity ratio stands at 7.55, with current and quick ratios of 1.32 and 0.96, respectively. Over the past year, the stock has fluctuated between a low of $253.30 and a high of $346.85.

Institutional Investor Activities

Institutional investors have been active in adjusting their holdings in Amgen. Notably, State Street Corp has increased its shareholdings by 1.2% in the third quarter, while Charles Schwab Investment Management raised its stake by 25.4%. Other notable adjustments include Geode Capital Management and Janus Henderson Group, reflecting deep interest in Amgen among institutional investors, who now own about 76.50% of the company's stock.

Insider Trading

In corporate developments, Amgen's Senior Vice President, Nancy A. Grygiel, sold 1,589 shares at an average price of $304.47 on February 5th. Following this transaction, she holds 7,210 shares valued at approximately $2.19 million. Insider trading activity reflects the interests and confidence levels of the company's management regarding its stock.

Dividend Increase Announcement

Amgen has also announced an increase in its quarterly dividend, set to be paid on March 7th. Shareholders of record on February 14th will receive a dividend of $2.38, up from $2.25. This change amounts to an annualized dividend of $9.52, and the dividend yield is currently 3.20%, albeit with a payout ratio marked at 126.09%.

About Amgen

Amgen Inc. is a leading biotechnology company focused on discovering, developing, manufacturing, and delivering innovative human therapeutics globally. Its product offerings include treatments for various medical conditions, ranging from autoimmune diseases to cancers, positioning the company as a significant player in the biopharmaceutical industry.

Amgen, Earnings, Estimates